A Phase 1, Open-Label, Randomized, Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of SLC-391 in Healthy Adult Subjects
Latest Information Update: 04 Aug 2022
At a glance
- Drugs SLC 391 (Primary)
- Indications Acute myeloid leukaemia; COVID 2019 infections; Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors SignalChem Lifesciences
Most Recent Events
- 28 Jul 2022 Status changed from recruiting to completed.
- 16 Mar 2022 New trial record